Considering The Future of Asthma Treatment

Video

Mark S. Forshag, MD, MHA, with GSK, shared some of his team's next steps in advancing asthma care specifically with trying to keep things simple for the patients and their physicians.

At AAAAI 2017, Mark S. Forshag, MD, MHA, with GSK, shared some of his team's next steps to be followed after the meeting. He explained that GSK had added a number of new products to its asthma portfolio since 2013, and some of them are only indicated for 18 and up, with Nucala indicated for patients down to age 12.

"The thing that we're trying to do is that there are a number of classes of medications that are available for inhaled therapy for asthma and other lung disorders. We've been trying to identify a once-a-day therapy in each of those classes and then package them in the same inhaler so that if a patient has to switch drugs, the device doesn't change - they don't have to relearn a new device. Just trying to keep things simple for them and their physicians," said Forshag.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Elizabeth Aby, MD | Credit: Minnesota Health Fairview
Prashant Singh, MD | Credit: University of Michigan
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Ali Rezaie, MD | Credit: X
Should We Reclassify Diabetes Subtypes?
Remo Panaccione, MD | Credit: University of Calgary
Francisca Joly, MD, PhD | Credit: The Transplantation Society
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
© 2024 MJH Life Sciences

All rights reserved.